

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 July 2023 (27.07.2023)



(10) International Publication Number
WO 2023/139534 A1

(51) International Patent Classification:

A61P 27/00 (2006.01) C07D 405/14 (2006.01)
A61P 37/00 (2006.01) C07D 491/107 (2006.01)
C07D 401/06 (2006.01) A61K 31/454 (2006.01)
C07D 401/14 (2006.01)

(21) International Application Number:

PCT/IB2023/050504

(22) International Filing Date:

20 January 2023 (20.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/302,246 24 January 2022 (24.01.2022) US

(71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: ADAMS, Christopher M.; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). CZABANIUK, Lara C.; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). FLOHR, Stefanie; Novartis Pharma AG, Postfach, 4002 Basel (CH). GESSIER, François; Novartis Pharma AG, Postfach, 4002 Basel (CH). HEDIGER, Michael Christoph; Novartis Pharma AG, Postfach, 4002 Basel (CH). HURTH, Konstanze; Novartis Pharma AG, Postfach, 4002 Basel (CH). LABBE-GIGUERE, Nancy; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). LIMA, Fabio; Novartis Pharma AG, Postfach, 4002 Basel (CH). PATEL, Tajesh; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). SENDZIK, Martin; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). SIMIC, Oliver; Novartis Pharma AG, Postfach, 4002 Basel (CH). VITREY, Angela; Novartis Pharma AG, Post-

fach, 4002 Basel (CH). VULPETTI, Anna; Novartis Pharma AG, Postfach, 4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF

(57) Abstract: Provided herein are compounds of formula (I) and pharmaceutical compositions thereof useful for treating diseases or disorders mediated by the complement factor B. (I).



WO 2023/139534 A1